Table 1 Baseline characteristics between the revised population tested by MNA and revised re-tested population by Monogram PsVN assay - revised PPAS MNA at D28 / Revised PPAS monogram at D28

From: Beta-variant recombinant SARS CoV-2 vaccine induces durable cross-reactive antibodies against Omicron BA variants

 

SANOFI D614- Revised tested with MNA (N = 71)

SANOFI D614- Revised retested with PsVN (N = 48)

Differences Revised retested minus reviseda

SANOFI B.1.351- Revised tested with MNA (N = 61)

SANOFI B.1.351- Revised retested with PsVN (N = 54)

Differences Revised retested minus reviseda

PFIZER BNTl62b2- Revised tested with MNA (N = 70)

PFIZER BNTI62b2 – Revised retested with PsVN (N = 60)

Differences Retested minus Reviseda

Sex: n (%)

Male

43 (60.6)

29 (60.4)

−0.15 (−17.76; 16.97)

39 (63.9)

34 (63.0)

−0.97 (−18.19; 16.12)

35 (50.0)

31 (51.7)

1.67 (−15.15; 18.34)

Female

28 (39.4)

19 (39.6)

0.15 (−16.97; 17.76)

22 (36.1)

20 (37.0)

0.97 (−16.12;18.19)

35 (50.0)

29 (48.3)

−1.67 (−18.34; 15.15)

Age category: n (%)

18–55 years

61 (85.9)

44 (91.7)

5.15 (−7.09; 16.90)

52 (85.2)

46 (85.2)

−0.06 (−13.66; 13.01)

59 (84.3)

52 (86.7)

2.38 (−10.36; 14.50)

56–64 years

8 (11.3)

4 (8.3)

−2.93 (−13.62; 9.54)

8 (13.1)

7 (13.0)

−0.15 (−12.68; 12.93)

8 (11.4)

7 (11.7)

0.24 (−10.97; 12.11)

≥65 years

2 (2.8)

0

−2.82 (−9.70; 4.87)

1 (1.6)

1 (1.9)

0.21 (−7.03; 8.25)

3 (4.3)

1 (1.7)

−2.62 (−10.32;5.10)

Age (year)

M

71

48

 

61

54

 

70

60

 

Mean (SD)

41.1 (13.2)

41.9 (10.7)

0.811 (−3.73; 5.35)

41.8 (11.2)

42.2 (10.8)

(−3.70; 0.384, 4.47)

40.9 (14.0)

40.7 (13.3)

−0.248 (−5.01;4.51)

Min;Max

19.0;73.0

19.0;64.0

 

22.0;68.0

23.0;68.0

 

20.0;69.0

20.0;68.0

 
  1. N: number of participants in Revised rPAS MNA at D28 or Revised PPAS Monogram at D28.
  2. M: number of participants available for the endpoint.
  3. 2-sided 95% Cl for the difference between proportions was based on the Wilson score method without continuity correction.
  4. The number of participants from the Revised PPAS Monogram at D28 (N) may differ from the number of available results (M) as some sample testing may generate nonvalid results (i.e., testing not meeting quality control, ZNG40-titer does not exceed specificity control parameter). The baseline demographics of participants’ whose samples were retested with the validated monogram PsVN assay are comparable to those tested with the MNA (Revised PPAS MNA at D28). Selection of participants based on availability of samples for this re-analysis and resulting comparability based on sex and age (assessed both categorically and continuously) indicate no systematic bias in the definition or composition of the subset of participants in this re-analysis.
  5. a2-sided 95% Cl for difference of mean age was based on the student t-distribution.
Back to article page